Lung Cancer Trials Ask AI to find trials
TerminatedNot applicableNCT03146117
Official study title

PET-DECT for Staging and Imaged Based Radiotherapy Planning in Lung Cancer

Study summary

The overall goal of this project is to investigate the diagnostic performance of integrated F-18 fluorodeoxyglucose-positron emission tomography (FDG-PET) and Dual Energy CT (DECT) imaging in determining the thoracic nodal status of small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC), and its impact on target volume delineation for image guided radiation therapy (IGRT) planning.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedNot specified

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Small cell lung cancer (SCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jun 21, 2018 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Medical University of South Carolina

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Medical University of South Carolina
Interventions being studied
Not specified
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→Small cell lung cancer (SCLC)→
Treatment approach
Radiation therapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

To be eligible for the study: (All answers must be "YES" for subject to be eligible.) 1. Subject must have a suspected SCLC or NSCLC. 2. Subject must be 18-90 years of age. 3. Subject must have been referred for a clinically indicated PET-CT. 4. Subject must provide written informed consent prior to any study-related procedures being performed. 5. Subject must be willing to comply with all clinical study procedures.

Reasons someone may not be able to joinExclusion criteria
  • The presence of the following excludes subjects from the study: (All answers must be "NO" for subject to be eligible.) 1. Subject is a pregnant or nursing female. Exclude the possibility of pregnancy:
  • By testing (serum or urine βHCG) within 24 hours before contrast agent administration, or
  • By surgical sterilization, or
  • Post-menopausal, with minimum one (1) year history without menses. 2. Subject has impaired renal function (eGFR\<30 mL/min). 3. Subject has an acute psychiatric disorder or is cognitively impaired. 4. Subject is using or is dependent on substances of abuse. 5. Subject is unwilling to comply with the requirements of the protocol. 6. Subject has an allergy against iodinated contrast agents and cannot be premedicated. 7. Subject is in acute unstable condition.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Medical University of South CarolinaCharleston, South Carolina

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 21, 2018. Always confirm current availability with the study team.

View original record ↗